The experimental drug fenebrutinib worked better than Aubagio, an approved therapy, for reducing relapse rates in MS, new ...
Please provide your email address to receive an email when new articles are posted on . Adults either continued to receive ublituximab or switched from teriflunomide to ublituximab in this 3-year open ...
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American ...
- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
A new method replicated the findings of a previous clinical trial of Tecfidera in people with relapsing-remitting MS, a study ...
SAN DIEGO — Ozanimod was associated with stable or improved cognition in nearly 90% of patients who received the drug for relapsing-remitting multiple sclerosis (RRMS), a new study showed. Results ...
TG Therapeutics, Inc. (NASDAQ: TGTX), announced the completion of enrollment in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the Company’s anti-CD20 monoclonal antibody, in ...
According to IQVIA data, the approved drug has an estimated market size of $145 million for the 12 months ended December 2025 ...
The test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis.
In the above studies in PPMS and RMS, GA Depot showed EDSS stabilization, irrespective of baseline EDSS scores. These EDSS findings suggest GA Depot's potential in slowing disability progression, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results